SynthesisThe Cochrane database of systematic reviews2000
Garlic for peripheral arterial occlusive disease.
Synthesis in The Cochrane database of systematic reviews, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Garlic for peripheral arterial occlusive disease.The Cochrane database of systematic reviews · 2013Pooled it
- Buflomedil for intermittent claudication.The Cochrane database of systematic reviews · 2013Pooled it
- Pooled it
- The Potential Role of Antioxidants in the Treatment of Peripheral Arterial Disease: A Systematic Review.Antioxidants (Basel, Switzerland) · 2022Review
- Motivations for Botanical Use by Socioeconomically Diverse, Urban Adults: Does Evidence Support Motivation?Journal of alternative and complementary medicine (New York, N.Y.) · 2017Article
- Garlic: a review of potential therapeutic effects.Avicenna journal of phytomedicine · 2014Review
Corrections and comments
- Updated by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommercially available preparations of garlic have been reported to have beneficial effects on some of the risk factors associated with atherosclerosis.
objectivesThe objective of this review was to assess the effects of garlic (both dried and non-powdered preparations) for the treatment of peripheral arterial occlusive disease. SEARCH STRATEGY: The reviewers searched the Cochrane Peripheral Vascular Diseases Group trials register, AMED, EMBASE, BIDS ISI, abstracts of relevant symposia and reference lists of relevant articles up to August 1998. The reviewers also contacted pharmaceutical companies, investigators and experts in garlic therapies. SELECTION CRITERIA: Randomised trials of garlic therapy in patients with lower limb atherosclerosis. The main outcomes were objective measures of progression of underlying atherosclerosis (e.g. ankle pressure measurements, treadmill testing) and subjective measures (e.g. symptom progression). DATA COLLECTION AND ANALYSIS: At least two reviewers extracted data and assessed trial quality independently. The reviewers contacted investigators to obtain information needed for the review that could not be found in published reports. MAIN
resultsOne eligible trial with 78 participants was found. Both men and women (aged 40-75) were included. The follow-up period was short, 12 weeks only. After twelve weeks of treatment, pain free walking distance increased from 161 to 207 m in the group on garlic and from 172 to 203 m in the placebo group. This was not a statistically significant difference. There was no difference in change of systolic or diastolic blood pressure, heart rate, ankle and brachial pressures. No severe side effects were observed and nine patients taking garlic (28%) and four patients taking placebo (12%) complained of a noticeable garlic smell. REVIEWER'S
conclusionsOne small trial of short duration found no effect on walking distance.
Indexed as
Identifiers
10796487What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.